Phaseline

Companies › Yaqrit

Yaqrit: clinical trials, targets and expected readouts

2 active drug programs in 18 registered trials: 10 Phase 2, 3 Phase 4, 3 Phase 1, 2 Phase 3; Gastroenterology, Genitourinary, Hematology, Infectious disease; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Filgrastim
Granulocyte colony stimulating factor receptor agonist
CSF3RPhase 2Acute-On-Chronic Liver Failure; Early-stage Breast Cancer; Diminished Ovarian Reserve; Allogeneic Granulocyte Donation …Aug 2028
Resatorvid (TAK-242)
Toll-like receptor 4 inhibitor
TLR4Phase 2Acute-On-Chronic Liver FailureAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06520163FilgrastimPhase 3Non-Hodgkin's LymphomaOncologyAug 2026
NCT05753618FilgrastimPhase 4Early-stage Breast CancerOncologyOct 2026
NCT02143830FilgrastimPhase 2Fanconi AnemiaHematologyDec 2026
NCT06649851FilgrastimPhase 2MGMT-Methylated GlioblastomaOncologyJan 2027
NCT07651475FilgrastimPhase 2R/R AMLOncologyMar 2027
NCT07012044FilgrastimPhase 1Acute Myeloid Leukemia Post Cytotoxic TherapyOncologyMar 2027
NCT04262843FilgrastimPhase 2Acute Lymphoblastic LeukemiaOncologyMay 2027
NCT06414889FilgrastimPhase 1RUNX1 Familial Platelet DisorderHematologyJun 2027
NCT06742463FilgrastimPhase 2Acute T Lymphpblastic Leukemia/LymphomaOncologyJun 2028
NCT06890039Resatorvid (TAK-242)Phase 2Acute-On-Chronic Liver FailureGastroenterologyAug 2028
NCT06890039FilgrastimPhase 2Acute-On-Chronic Liver FailureGastroenterologyAug 2028
NCT07585136FilgrastimPhase 1Bone Marrow Failure SyndromeHematologyDec 2028
NCT01624805FilgrastimPhase 2Aplastic AnemiaHematologyJun 2029
NCT05796570FilgrastimPhase 2Acute Myeloid LeukemiaOncologySep 2029
NCT00785525FilgrastimPhase 3HealthyOtherJan 2030
NCT07871825FilgrastimPhase 4Diminished Ovarian ReserveGenitourinaryFeb 2030
NCT02015013FilgrastimPhase 2Idiopathic CD4-PositiveInfectious diseaseOct 2030
NCT01553214FilgrastimPhase 4Allogeneic Granulocyte DonationInfectious diseaseJan 2032

Targets

TLR4 (1) CSF3R (1)

Companies with the same targets

Nanjing King-Friend Biochemical Pharmaceutical CSL Behring Savara Spectrum Pharmaceuticals Qilu Pharmaceutical Kexing Biopharm

Companies built like this

Nefro Avillion Clinical Development LG Chem TLC Biopharmaceuticals GrandPharma (China) Brii Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.